Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts, and prostate cell lines

ABSTRACT: ATAC-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts, and prostate cell lines

PROVIDER: PRJNA798395 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17655800_1.fastq.gz	Fastqsanger.gz
	SRR17655800_2.fastq.gz	Fastqsanger.gz
	SRR17655801_1.fastq.gz	Fastqsanger.gz
	SRR17655801_2.fastq.gz	Fastqsanger.gz
	SRR17655802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 172

Similar Datasets

RNA-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts

Project description:RNA-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts

| PRJNA751853 | ENA

RNA-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts

Project description:Transcriptome profiling analysis was performed in 22 human prostate cancer organoids, 6 patient-derived xenografts (PDXs) and 7 cell lines.

2021-08-04 | GSE181374 | GEO

ATAC-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts, and prostate cell lines

Project description:Chromatin accessibility profiling analsis was performed in 22 human prostate cancer organoid, 6 Xenografts and 7 cell lines

2022-01-21 | GSE193917 | GEO

ChIP-Seq in MSK-PCa3 Prostate Cancer Organoids of FOSL1, TAZ, TEAD1, YAP

Project description:Genome-wide mapping of FOSL1, YAP, TAZ and TEAD1 binding sites in MSK-PCa3 cells

2022-02-17 | GSE196732 | GEO

Expression data from patient and primary xenografts esophageal tumour samples

Project description:Microarrays were used to assess differences between 1) human tumours that did and did not engraft, 2) human tumours and their matched primary xenografts, 3) early and late passage primary xenografts and 4) small and large primary xenografts for a series of esophageal patient and primary xenograft tumours

2015-01-11 | GSE58870 | GEO

Analysis of genetic changes in MCF10A series cells and MCFDCIS derived xenografts

Project description:MCF10A series is one of the few human models of breast tumor progression. A derivative of MCF10A cells is the MCFDCIS, which reproducibly forms comedo DCIS-like lesions that spontaneously progress to invasive tumors. We used this model to explore the relative importance of myoepithelial cells and stromal fibroblasts in the in situ to invasive breast carcinoma transition. We use Affymetrix 11K XbaI or 250K StyI SNP arrays to analyze the MCF10A series cells and MCFDCIS derived xenografts for copy number changes and LOH (loss of heterozygosity). Keywords: Cell line, xenografts of time course/co-injection groups, different cell types isolated from xenografts

2008-03-07 | GSE10747 | GEO

DNA methylation analysis of breast cancer patient-derived xenografts and organoids

Project description:To understand if the generation of xenograft and organoid models of breast cancer alters DNA methylation, we compared the genome-wide methylation profile of matching patient tumors, patient derived xenografts, and organoid cultures derived from xenografts.

2022-01-09 | GSE186747 | GEO

Patient-derived Human Breast Cancer Xenografts

Project description:Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of SCID/Beige and NOD/SCID/IL2γ-receptor null (NSG) mice, under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (~23% and ~19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing unique 25 patients. Most tumors yielding xenografts were “triple-negative” (ER-PR-HER2+) (n=19). However, we established lines from three ER-PR-HER2+ tumors, one ER+PR-HER2-, one ER+PR+HER2- and one “triple-positive” (ER+PR+HER2+) tumor. Serially passaged xenografts show biological consistency with the tumor of origin, are phenotypic stability across multiple transplant generations at the histological, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses. Xenografts representing 12 patients, including two ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis.

2013-05-30 | GSE46106 | GEO

Thoracic patient-derived xenografts

Project description:Thoracic patient-derived xenografts

| PRJNA339191 | ENA

Patient-derived Human Breast Cancer Xenografts

2013-05-30 | E-GEOD-46106 | biostudies-arrayexpress